MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,880.00
-60.00 (-0.86%)
Dec 10, 2025, 3:30 PM KST
70.51%
Market Cap237.87B
Revenue (ttm)2.47B
Net Income (ttm)-14.57B
Shares Out34.28M
EPS (ttm)-426.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume497,605
Average Volume1,285,078
Open6,960.00
Previous Close6,940.00
Day's Range6,800.00 - 7,140.00
52-Week Range2,750.00 - 8,650.00
Beta0.54
RSI58.24
Earnings DateNov 11, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Seong-Jin Kim
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.